SAN DIEGO, Feb. 4, 2014 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company
will report its fourth quarter and year-end 2013 financial results
after the Nasdaq market closes on Thursday, February 6, 2014.
Neurocrine will then host a live conference call and webcast
to discuss its financial results and provide a Company update
Thursday afternoon, February 6, 2014
at 5:00 p.m. Eastern Time
(2:00 p.m. Pacific Time).
Participants can access the live conference call by dialing
800-862-9098 (US) or 785-424-1051 (International) using the
conference ID: NBIX. The call can also be accessed via the webcast
through the Company's website at http://www.neurocrine.com.
If you are unable to attend the webcast and would like further
information on this announcement please contact the Investor
Relations Department at Neurocrine Biosciences at (858) 617-7600.
A replay of the conference call will be available
approximately one hour after the conclusion of the call by dialing
800-723-8184 (US) or 402-220-2668 (International) using the
conference ID: NBIX. The call will be archived for one month.
Neurocrine Biosciences, Inc. is a clinical stage drug discovery
company primarily focused on neurological and endocrine based
diseases and disorders. The Company discovers and develops
innovative pharmaceuticals, in diseases with high unmet medical
needs or where the existing drug classes are inadequate, through a
disciplined yet entrepreneurial process. Utilizing a portfolio
approach to drug discovery, Neurocrine has multiple small molecule
drug candidates at various stages of pharmaceutical development.
Neurocrine's two lead late stage clinical programs are elagolix, a
GnRH antagonist for women's health that is partnered with AbbVie
Inc., and a wholly owned VMAT2 inhibitor for the treatment of
movement disorders. Neurocrine intends to maintain certain
commercial rights to its VMAT2 inhibitor for evolution into a
fully-integrated pharmaceutical company. Neurocrine
Biosciences, Inc. news releases are available through the Company's
website via the internet at http://www.neurocrine.com.
SOURCE Neurocrine Biosciences, Inc.